Krystal Biotech Q3 net income triples
I'm PortAI, I can summarize articles.
Krystal Biotech reported a significant increase in Q3 2025 net income, tripling to $79.4 million from $27.2 million in Q3 2024. Product revenue rose to $97.8 million, up from $83.8 million. The company launched VYJUVEK in Germany and plans to continue pricing negotiations in Germany until at least the second half of 2026. The gross margin for the quarter was an impressive 96%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments